Eli Samaha Sells 37,799 Shares of Theravance Biopharma (NASDAQ:TBPH) Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 37,799 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total transaction of $642,583.00. Following the sale, the insider directly owned 9,174,453 shares of the company’s stock, valued at approximately $155,965,701. This trade represents a 0.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Eli Samaha also recently made the following trade(s):

• On Tuesday, June 30th, Eli Samaha sold 25,027 shares of Theravance Biopharma stock. The shares were sold at an average price of $17.13, for a total transaction of $428,712.51.
• On Monday, June 29th, Eli Samaha sold 273,871 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.23, for a total transaction of $4,718,797.33.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $16.93 on Friday. The firm has a market cap of $872.74 million, a price-to-earnings ratio of 7.70 and a beta of 0.17. The firm has a fifty day moving average price of $16.57 and a 200 day moving average price of $17.28. Theravance Biopharma, Inc. has a fifty-two week low of $10.82 and a fifty-two week high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. As a group, research analysts predict that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Wall Street Zen downgraded Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Oppenheimer cut Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. Zacks Research downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. BTIG Research cut Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Monday. Finally, TD Cowen upped their price objective on Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. One research analyst has rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, Theravance Biopharma has an average rating of “Hold” and an average price target of $21.40.

Institutional Investors Weigh In On Theravance Biopharma

Several large investors have recently added to or reduced their stakes in TBPH. Quarry LP bought a new stake in shares of Theravance Biopharma in the 3rd quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd increased its position in shares of Theravance Biopharma by 107.4% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Theravance Biopharma by 26.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC raised its holdings in Theravance Biopharma by 20,269.6% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares during the period. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.